Oxford Biomedica

OXB.L

Oxford, United Kingdom· Est. 1995

oxb.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

OXB.L · Stock Price

GBP 6.59+3.64 (+123.39%)

Market Cap: $1.1B

Historical price data

Market Cap: $1.1BPipeline: 12 drugsPatents: 5Founded: 1995Employees: 1000+HQ: Oxford, United Kingdom

Sector Ranking#33 in Cell & Gene Therapy

Overview

Oxford Biomedica (OXB) is a mission-driven, global CDMO dedicated to enabling the development and manufacture of life-changing cell and gene therapies. The company has successfully transitioned from an internal developer to a pure-play, innovation-led service provider, achieving strong revenue growth and operating EBITDA profitability. Its strategy leverages deep expertise in lentiviral and AAV vector platforms, a global manufacturing footprint, and a client-centric model to capitalize on the rapidly expanding advanced therapies market.

OncologyGenetic DiseasesRare DiseasesInfectious Diseases

Technology Platform

Proprietary viral vector platforms including the LentiVector™/TetraVecta™ system for lentivirus and the inAAVate™ platform for accelerated, high-yield AAV manufacturing, alongside expertise in adenovirus and other viral vectors.

Pipeline

12 drugs in pipeline

Drug	Indication	Stage
TroVax + IL-2	Carcinoma, Renal Cell	Phase 2
TroVax + Interleukin-2	Carcinoma, Renal Cell	Phase 2
TroVax® + Placebo	Ovarian Cancer	Phase 2
TroVax	Colorectal Neoplasms	Phase 2
Docetaxel + TroVax	Hormone Refractory Prostate Cancer	Phase 2

Opportunities

The company is poised to capitalize on the exponential growth of the cell and gene therapy market, where viral vector manufacturing is a critical bottleneck.

Its proprietary platforms and global GMP network position it to win large-scale, long-term commercial manufacturing contracts as client therapies advance.

Risk Factors

Key risks include high dependence on the success and funding of client pipelines, intense competition in the CDMO space potentially pressuring pricing, and the operational risks associated with scaling complex biological manufacturing processes consistently.

Competitive Landscape

OXB competes with large, diversified CDMOs (e.g., Lonza, Catalent) and specialized viral vector peers. Its differentiation lies in its deep lentiviral heritage, proprietary AAV platform for speed/yield, and a pure-play, globally integrated manufacturing network dedicated solely to cell and gene therapy vectors.